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clinical implications of basic research
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Elizabeth G. Phimister, Ph.D., Editor
Influenza — Time to Target the Host?
J. Kenneth Baillie, M.D., Ph.D., and Paul Digard, Ph.D.
Influenza A viruses make formidable combat-
ants. Their ubiquity and diversity in nature, cou-
pled with a rapid capacity to evolve, render them 
one of the most mutable pathogens faced by hu-
manity. The avian influenza A (H7N9) outbreak 
in China, which shows many troubling features, 
would be a timely reminder of the threat, if any 
were needed.
Vaccines and antiviral drugs are available to 
prevent and treat infection, but both are ren-
dered less effective by the variability of the vi-
rus. In particular, our ability to intervene using 
specific therapies in critically ill patients with 
severe influenza infection is limited, with the 
current antiviral agents showing disappointing 
results even in the absence of obvious viral re-
sistance.1
In contrast to the virus, humans do not 
change quickly. It is therefore an enticing strat-
egy to try to overpower influenza not by target-
ing the virus itself but rather by finding ways to 
make our own cells less permissive to viral rep-
lication. Such a strategy may limit the ability of 
the virus to evolve resistance.
Morita et al. therefore set out to identify hu-
man lipid products that restrict influenza repli-
cation in vitro.2 Unlike models in many other 
diseases, cell-culture models in influenza infec-
tion have direct conceptual relevance to clinical 
practice: if we can find ways to make cells in a 
petri dish less supportive of viral replication, it 
follows that the same treatments may restrict 
viral replication in a whole organism.
The investigators screened libraries of bioac-
tive lipids, including prostaglandins, leukotri-
enes, and numerous other mediators, to find 
compounds that restricted influenza replication 
in a human cell line (Fig. 1). Notably, all these 
lipids are endogenous mediators produced by 
host cells, derived from endogenous lipids. One 
such mediator produced when n−3 polyunsatu-
rated fatty acids (fish oils) are available is pro-
tectin D1. This turned out to be the most potent 
inhibitor of viral replication; it appears to work 
by inhibiting the nuclear export of viral mRNA.
When Morita et al. characterized lipid media-
tors in the whole organism, using mass spectros-
copy to quantify lipid species (lipidomics) in a 
mouse model of severe influenza infection, they 
found that the protective mediator protectin 
D1 was down-regulated in the lungs of infected 
animals.
The authors then administered protectin D1 
intravenously to mice before infecting them intra-
tracheally with influenza virus and found that 
the compound was protective against influenza. 
So far so good, and the magnitude of the effect 
was impressive, given the generally modest ef-
fects of protectin D1 on virus replication in cell 
culture.
However, a major roadblock in translational 
research is the ability to find interventions that 
are active at a clinically relevant time point. Pa-
tients do not usually present early in disease 
progression; in many cases, substantial organ 
failure has ensued before patients with severe 
influenza infection present to any medical ser-
vices. For this reason, it is highly important that 
protectin D1 was effective in altering the course 
of disease in mice, even when treatment was 
initiated 2 days after infection with influenza 
virus. When protectin D1 was administered in 
combination with the antiviral agent peramivir, 
there was an impressive reduction in mortality. 
Without treatment, all the mice died. With 
treatment, they all survived. With peramivir 
treatment alone, approximately 35% of the mice 
survived.
Does protectin D1 have the potential to be-
come a new therapy for influenza infection? 
Perhaps. It has some advantages over other 
compounds as it sets out on the long road to-
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITY OF EDINBURGH LIB on June 6, 2014. For personal use only. No other uses without permission. 
 Copyright © 2013 Massachusetts Medical Society. All rights reserved. 
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
n engl j med 369;2 nejm.org july 11, 2013192
1
Phimister
7/11/13
6/25/13
AUTHOR PLEASE NOTE:
Figure has been redrawn and type has been reset
Please check carefully
Author
Fig #
Title
ME
DE
Artist
Issue date
COLOR FIGURE
Draft 4
Digard
Knoper
Host-derived lipid mediators
COOH
CH3
Arachidonic acid–
derived products
COOH
CH3
Docosahexaenoic acid–
derived products
COOH
CH3
Eicosapentaenoic acid–
derived products
OH
COOH
OH
COOH
OH
COOH
OH
Varying degrees of
influenza replication
Specific inhibitory compounds tested for efficacy in mice
12-HETE
Protectin D1
17-HdoHE
Figure 1. Identification of Protectin D1 as a Potential Therapeutic Agent.
In the discovery process used to identify protectin D1 as a potential therapeutic agent to modulate the host response in severe influenza 
infection, a wide range of different host lipid mediators were tested in cell-culture models of viral replication. Candidate mediators that 
restricted replication in vitro were then tested in mouse models of severe disease. With protectin D1, mice had significantly reduced mor-
tality, whereas mice treated with 12-hydroxyeicosatetraenoic acid (12-HETE) or 17-hydroxydocosahexaenoic acid (17-HdoHE) had severe 
illness and high mortality, similar to infected animals left untreated.
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ward clinical practice. It is an endogenous me-
diator and appears to be potently active, albeit 
in combination with another drug, in a mam-
malian model. However, some common limita-
tions of lipid mediators, including poor oral 
bioavailability, short half-life, and potential tox-
icity,3 are also likely to apply and may restrict 
initial drug-development efforts to the intensive 
care unit. Nevertheless, the potential of this 
compound in critical illness may extend beyond 
influenza infection — evidence exists for poten-
tially beneficial effects in animal models of other 
life-threatening conditions, including peritonitis, 
asthma, and acute kidney injury.4 Another pos-
sibility is that host variation in the key protectin 
D1 pathways, such as the enzyme 12/15 lipoxy-
genase, may explain some of the variation in in-
dividual susceptibility.5
As with all therapies in the first stage of de-
velopment, the odds are stacked against protec-
tin D1. If it fails, perhaps the most lasting effect 
of this work will be the successful demonstra-
tion of the principle that screening for host lipid 
factors that restrict replication can result in via-
ble therapeutic candidates.
Disclosure forms provided by the authors are available with 
the full text of this article at NEJM.org.
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